Anti-Therapeutic Action: Limited in vivo efficacy due to high plasma protein binding

Discovery of the antifungal compound ilicicolin K through genetic activation of the ilicicolin biosynthetic pathway in Trichoderma reesei

Scientists used genetic engineering to activate a dormant gene cluster in the fungus Trichoderma reesei, enabling it to produce the antifungal compound ilicicolin H in high quantities. During this process, they discovered a new related compound called ilicicolin K that shows even stronger antifungal properties. These compounds could potentially overcome limitations of current antifungal treatments, especially against drug-resistant fungi like Candida auris.

Read More »
Scroll to Top